Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04931992

Acronym

MOLAM

Enrollment

100

Registered

2021-06-18

Start date

2021-06-01

Completion date

2021-12-31

Last updated

2021-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML eventually relapse. Some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. The outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. This multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.

Interventions

OTHERNo intervention

Retrospective analysis

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 61 Years

Inclusion criteria

* Patients between 18 and 61 years * Diagnosis between 2010 and 2019 * Core binding factor and/or NPM1 acute myeloid leukemia * First complete remission after induction therapy * Measurable residual disease measurement after end of consolidation therapy

Exclusion criteria

* Acute promyelocytic leukemia * Allogeneic stem cell transplantation in CR1

Design outcomes

Primary

Measure	Time frame
Event-free survival	Up to 5 years

Secondary

Measure	Time frame
Overall survival	Up to 5 years

Countries

France

Contacts

Primary ContactCorentin Orvain, MD, PhD

corentin.orvain@chu-angers.fr+33241354475

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026